{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-035258","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.807412+00:00","generated_at":"2026-06-21T05:42:09.124265+00:00","sec_items":["1.01","2.01","5.06","9.01","5.02","3.02","4.01","3.01","3.03","5.03","5.01","5.05","8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"ZyVersa Therapeutics completes de-SPAC merger with Larkspur; 99% of public shares redeemed","bullets":["Larkspur merged with ZyVersa on Dec 12, 2022; name changed to ZyVersa Therapeutics, Inc. (ZVSA).","Public stockholders redeemed 7,667,029 shares (~$77.99M) at $10.17/share, leaving ~100K public shares.","PIPE investment of $8.635M via Series A Preferred and warrants at $1,000 per unit, conversion price $10.","Post-deal: 9,081,922 common shares outstanding; exchange ratio of 5.037 for Old ZyVersa shares.","Ownership: Larkspur Health LLC (16.8%), INCON Co., Ltd. (20.4%), Stephen Glover (15.1%), Daniel O'Connor (16.8%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-035258","json":"https://secwatch.observer/filing/0001493152-22-035258.json","markdown":"https://secwatch.observer/filing/0001493152-22-035258.md","text":"https://secwatch.observer/filing/0001493152-22-035258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:42:09.124265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"066ccfaea1","claim":"Min-Chul Park was appointed as Director at ZyVersa Therapeutics, Inc..","evidence_excerpt":"Stephen C. Glover, Robert Finizio, Min-Chul Park, and Daniel J. O’Connor were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"16614f7208","claim":"Nicholas A. LaBella was appointed as Chief Scientific Officer at ZyVersa Therapeutics, Inc..","evidence_excerpt":"Nicholas A. LaBella was appointed Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"303ff7563e","claim":"Stephen C. Glover was appointed as Director at ZyVersa Therapeutics, Inc..","evidence_excerpt":"Stephen C. Glover, Robert Finizio, Min-Chul Park, and Daniel J. O’Connor were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3c17a120b6","claim":"Daniel J. O’Connor was appointed as Director at ZyVersa Therapeutics, Inc..","evidence_excerpt":"Stephen C. Glover, Robert Finizio, Min-Chul Park, and Daniel J. O’Connor were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"65b8c082d7","claim":"Raj Mehra departed as Director at ZyVersa Therapeutics, Inc..","evidence_excerpt":"David S. Briones, Raj Mehra, Gregory Skalicky, and Christopher Twitty ceased serving on the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"68eb9938c6","claim":"Stephen C. Glover was appointed as President and Chief Executive Officer at ZyVersa Therapeutics, Inc..","evidence_excerpt":"Stephen C. Glover was appointed President and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"bd63ae6fc0","claim":"Gregory Skalicky departed as Director at ZyVersa Therapeutics, Inc..","evidence_excerpt":"David S. Briones, Raj Mehra, Gregory Skalicky, and Christopher Twitty ceased serving on the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c71bf70ae1","claim":"Karen Cashmere was appointed as Chief Commercial Officer at ZyVersa Therapeutics, Inc..","evidence_excerpt":"Karen Cashmere was appointed Chief Commercial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"d192ee5bf6","claim":"David S. Briones departed as Director at ZyVersa Therapeutics, Inc..","evidence_excerpt":"David S. Briones, Raj Mehra, Gregory Skalicky, and Christopher Twitty ceased serving on the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ef44ae16aa","claim":"Christopher Twitty departed as Director at ZyVersa Therapeutics, Inc..","evidence_excerpt":"David S. Briones, Raj Mehra, Gregory Skalicky, and Christopher Twitty ceased serving on the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fc310842eb","claim":"Robert Finizio was appointed as Director at ZyVersa Therapeutics, Inc..","evidence_excerpt":"Stephen C. Glover, Robert Finizio, Min-Chul Park, and Daniel J. O’Connor were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fcfd326673","claim":"Peter Wolfe was appointed as Chief Financial Officer and Secretary at ZyVersa Therapeutics, Inc..","evidence_excerpt":"Peter Wolfe was appointed Chief Financial Officer and Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Secretary"}],"fact_type":"executive_change"},{"claim_id":"316746d48d7addc27db34d3e1a9f49fd16543acb","claim":"ZyVersa Therapeutics, Inc.: Adopted a new Code of Business Conduct and Ethics.","evidence_excerpt":"Effective upon the Closing Date, in connection with the consummation of the Business Combination, the Board adopted a new Code of Business Conduct and Ethics, which is applicable to all employees, officers and directors of the Company, which is available on the Company’s website at https://zyversa.com .","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"}],"fact_type":"governance_change"},{"claim_id":"65e3f1be3f58b37eb8508d38460366b65ddd8329","claim":"ZyVersa Therapeutics, Inc.: Company ceased to be a shell company as a result of the Business Combination.","evidence_excerpt":"As a result of the Business Combination, the Company ceased to be a shell company.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"}],"fact_type":"governance_change"},{"claim_id":"6763a446a46e5c7971dc32bac374f7ff1c4b7544","claim":"ZyVersa Therapeutics, Inc.: Adopted amended and restated bylaws.","evidence_excerpt":"and the Company adopted amended restated bylaws pursuant to an Amended and Restated Bylaws (the “ Amended and Restated Bylaws ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"afdf58c5ac018df22ca6f3c75d9ecffb22f0489f","claim":"ZyVersa Therapeutics, Inc.: Amended and restated certificate of incorporation pursuant to Second Amended and Restated Certificate of Incorporation.","evidence_excerpt":"In connection with the consummation of the Business Combination, the Company amended and restated its certificate of incorporation, effective as of the Closing Date, pursuant to a Second Amended and Restated Certificate of Incorporation (as amended, the “ Second Amended and Restated Certificate of Incorporation ”), and the Company adopted amended restated bylaws pursuant to an Amended and Restated Bylaws (the “ Amended and Restated Bylaws ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"5ac0615faef9a52adb07bace4b3e4714c62ad75a","claim":"ZyVersa Therapeutics, Inc. underwent a change of control involving ZyVersa Therapeutics, Inc. (Florida corporation) (closed 2022-12-12).","evidence_excerpt":"On December 12, 2022, the parties consummated the Business Combination pursuant to the terms of that certain Business Combination Agreement, dated July 20, 2022, as amended (the “Business Combination Agreement”) by and among ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (“Merger Sub”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"ZyVersa Therapeutics, Inc. (Florida corporation)"},{"label":"Closing","value":"2022-12-12"}],"fact_type":"ma_transaction"},{"claim_id":"014164ccc017679a8f10d0172b7e46ae03aa36e6","claim":"ZyVersa Therapeutics, Inc. entered into Business Combination Agreement with Larkspur, Larkspur Merger Sub, Inc., and the Securityholder Representative (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, the parties consummated the Business Combination pursuant to the terms of that certain Business Combination Agreement, dated July 20, 2022, as amended (the “Business Combination Agreement”) by and among ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (“Merger Sub”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Larkspur, Larkspur Merger Sub, Inc., and the Securityholder Representative"},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"},{"claim_id":"01d6dcf7f52409da07196561c9ea8f2d18e29101","claim":"ZyVersa Therapeutics, Inc. entered into Series B Registration Rights Agreement with the Purchasers of the Series B Shares (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, in connection with the consummation of the Business Combination, Larkspur and the Purchasers of the Series B Shares entered into a Registration Rights Agreement (the “Series B Registration Rights Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"the Purchasers of the Series B Shares"},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"},{"claim_id":"1482064db0d114227851bd548b9c2dc375908282","claim":"ZyVersa Therapeutics, Inc. entered into Lock-Up Agreements with the Key ZyVersa Shareholders and stockholders of Old ZyVersa (effective 2022-12-12).","evidence_excerpt":"In connection with the consummation of the Business Combination, the Company, the Key ZyVersa Shareholders and stockholders of Old ZyVersa, entered into the Lock-Up Agreements as contemplated by the Business Combination Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"the Key ZyVersa Shareholders and stockholders of Old ZyVersa"},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"},{"claim_id":"937c0641aeb578c1a07326b30dbd486e59cce674","claim":"ZyVersa Therapeutics, Inc. entered into PIPE Registration Rights Agreement with the PIPE Investors (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, in connection with the consummation of the Business Combination, the Company and the PIPE Investors entered into a Registration Rights Agreement (the “PIPE Registration Rights Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the PIPE Investors"},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"},{"claim_id":"e9c35bf80a1c5eb45581cb10a169439bfd7d7d6c","claim":"ZyVersa Therapeutics, Inc. entered into Amended and Restated Registration Rights Agreement with the Sponsor and certain persons and entities holding securities of the Company (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, substantially concurrently with the consummation of the Business Combination, the Company, the Sponsor and certain persons and entities holding securities of the Company entered into the Amended and Restated Registration Rights Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"the Sponsor and certain persons and entities holding securities of the Company"},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}